The induction of GnT-III or ERK suggests potential strategies to enhance the efficacy of differentiation therapy, potentially offering new avenues for therapeutic intervention in conditions like CML where differentiation defects are implicated. This evidence concerns the gene MGAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.